Human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in an HIV-positive patient coinfected with human T lymphotropic virus type 2 following initiation of antiretroviral therapy

Clinical Infectious Diseases

Volumn 45, Issue 9, 2007, Pages

  Toro, Carlos ^a   Blanco, Francisco ^a   García Gascó, Pilar ^a   Sheldon, Julie ^a   Benito, José M ^a   Rallón, Norma I ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMOXICILLIN; ANTIRETROVIRUS AGENT; EMTRICITABINE; LAMIVUDINE; RITONAVIR PLUS ATAZANAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CASE REPORT; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG ABUSE; DRUG RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; NEUROTOXICITY; PRIORITY JOURNAL; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; SUPERINFECTION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MALE; PARAPARESIS, TROPICAL SPASTIC;

EID: 35348838368     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522172     Document Type: Article

References (12)

1. Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
2. Shelbourne S, Montes M, Hamill R. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167-70.
3. Araujo A, Silva M. The HTLV-1 neurological complex. Lancet Neurol 2006; 5:1068-76.
4. Roucoux D, Murphy E. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev 2004; 6:144-54.
5. Toro C, Rodés B, Bassani S, et al. Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. J Clin Virol 2005;33:65-70.
6. Toro C, Rodes B, Poveda E, Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003; 75:102-4.
7. Epple H, Loddenkemper C, Kunkel D, et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 2006; 108:3072-8.
8. Soriano V, Gutierrez M, Bravo R, Diaz F, Olivan J, Gonzalez-Lahoz J. Severe myopathy in an injection drug user coinfected with HIV type 1 and human T cell leukemia virus type II. Clin Infect Dis 1994; 19:350-1.
9. Machuca A, Soriano V. In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. J Acquir Immune Defic Syndr 2000; 24:189-93.
10. Turci M, Pilotti E, Ronzi P, et al. Coinfection with HIV-1 and human T-cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr 2006; 41:100-6.
11. Oh U, Grant C, Griffith C, Fugo K, Takenouchi N, Jacobson S. Reduced Foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus type 1 infection. J Infect Dis 12006; 193:1557-66.
12. Shelburne S, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.